{"id":"in-prohibited-SO3068E","category":"india-prohibited","passed":true,"checks":[{"description":"Answers Yes","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001029,"latencyMs":7055,"response":"Yes. In India, “Acetyl Salicylic acid + Ethoheptazine” is prohibited for manufacture, sale and distribution under Section 26A of the Drugs and Cosmetics Act (S.O. 3068(E), 11 June 2026). [2]"}
{"id":"in-prohibited-SO3077E","category":"india-prohibited","passed":true,"checks":[{"description":"Answers Yes","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.000977,"latencyMs":3797,"response":"Yes. The fixed-dose combination Aloe vera + Vitamin E + Herbal is prohibited in India under Section 26A of the Drugs and Cosmetics Act, by S.O. 3077(E), dated 11 June 2026. [1]"}
{"id":"in-prohibited-SO3070E","category":"india-prohibited","passed":true,"checks":[{"description":"Answers Yes","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001181,"latencyMs":5648,"response":"Yes. In India, the fixed-dose combination amoxicillin + serratiopeptidase + *Lactobacillus sporogenes* is prohibited for manufacture, sale and distribution under Section 26A of the Drugs and Cosmetics Act [2]."}
{"id":"in-prohibited-SO3288E","category":"india-prohibited","passed":true,"checks":[{"description":"Answers Yes","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001017,"latencyMs":11725,"response":"Yes. In India, the fixed-dose combination bismuth ammonium citrate + papain is prohibited for manufacture, sale and distribution under Section 26A of the Drugs and Cosmetics Act (S.O. 3288(E), dated 2 August 2024). [2]"}
{"id":"in-prohibited-SO3414E","category":"india-prohibited","passed":true,"checks":[{"description":"Answers Yes","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.00116,"latencyMs":4900,"response":"Yes. Cephalexin monohydrate + serratiopeptidase is prohibited in India for manufacture, sale and distribution under Section 26A of the Drugs and Cosmetics Act (S.O. 3414(E), 2 August 2024) [2]."}
{"id":"in-prohibited-SO3359E","category":"india-prohibited","passed":true,"checks":[{"description":"Answers Yes","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001036,"latencyMs":5782,"response":"Yes. In India, the fixed-dose combination of chlorpheniramine maleate + naphazoline HCl + hydroxy propyl methyl cellulose is prohibited for manufacture, sale and distribution under Section 26A of the Drugs and Cosmetics Act, by S.O. 3359(E) dated 2 August 2024. [3]"}
{"id":"in-prohibited-SO3290E","category":"india-prohibited","passed":true,"checks":[{"description":"Answers Yes","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001141,"latencyMs":6341,"response":"Yes. In India, the fixed-dose combination of cyproheptadine hydrochloride, tricholine citrate, thiamine hydrochloride, riboflavine and pyridoxine hydrochloride is prohibited for manufacture, sale and distribution under Section 26A of the Drugs and Cosmetics Act [3]."}
{"id":"in-prohibited-SO3346E","category":"india-prohibited","passed":true,"checks":[{"description":"Answers Yes","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001303,"latencyMs":5671,"response":"Yes. India’s CDSCO lists the fixed-dose combination **divalproex sodium + levetiracetam** as prohibited for manufacture, sale and distribution under Section 26A of the Drugs and Cosmetics Act (S.O. 3346(E), 2 August 2024). [4]"}
{"id":"in-prohibited-SO3340E","category":"india-prohibited","passed":true,"checks":[{"description":"Answers Yes","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001143,"latencyMs":6110,"response":"Yes. In India, the fixed-dose combination flavoxate hydrochloride + ofloxacin is prohibited for manufacture, sale and distribution under Section 26A of the Drugs and Cosmetics Act (S.O. 3340(E), 2 August 2024) [3]."}
{"id":"in-prohibited-SO3316E","category":"india-prohibited","passed":true,"checks":[{"description":"Answers Yes","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001022,"latencyMs":5690,"response":"Yes. India’s CDSCO lists the fixed-dose combination **Glucosamine hydrochloride + Diacerein + Menthol + Camphor + Capsaicin** as prohibited for manufacture, sale and distribution under Section 26A of the Drugs and Cosmetics Act, by S.O. 3316(E), dated 2 August 2024. [2]"}
{"id":"in-prohibited-SO3425E","category":"india-prohibited","passed":true,"checks":[{"description":"Answers Yes","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001039,"latencyMs":6263,"response":"Yes. This fixed-dose combination is listed as prohibited for manufacture, sale and distribution in India. The specific CDSCO notification or entry was not included in the retrieved evidence for this question, so I cannot verify its notification details here."}
{"id":"in-prohibited-SO3388E","category":"india-prohibited","passed":true,"checks":[{"description":"Answers Yes","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001215,"latencyMs":4786,"response":"Yes. In India, the fixed-dose combination of levocetirizine + phenylephrine HCl + paracetamol is prohibited for manufacture, sale and distribution under Section 26A of the Drugs and Cosmetics Act (S.O. 3388(E), dated 2 August 2024). [4]"}
{"id":"in-prohibited-SO3330E","category":"india-prohibited","passed":true,"checks":[{"description":"Answers Yes","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001113,"latencyMs":4014,"response":"Yes. In India, the fixed-dose combination minoxidil + aminexil is prohibited for manufacture, sale and distribution under Section 26A of the Drugs and Cosmetics Act, by S.O. 3330(E) dated 2 August 2024. [2]"}
{"id":"in-prohibited-SO3369E","category":"india-prohibited","passed":true,"checks":[{"description":"Answers Yes","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.000999,"latencyMs":5262,"response":"Yes. The combination is prohibited in India under Section 26A of the Drugs and Cosmetics Act, by S.O. 3369(E) dated 2 August 2024. [2]"}
{"id":"in-prohibited-SO3376E","category":"india-prohibited","passed":true,"checks":[{"description":"Answers Yes","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001076,"latencyMs":4500,"response":"Yes. This fixed-dose combination is prohibited in India for manufacture, sale and distribution under Section 26A of the Drugs and Cosmetics Act (S.O. 3376(E), dated 2 August 2024). [3]"}
{"id":"in-prohibited-SO3079E","category":"india-prohibited","passed":true,"checks":[{"description":"Answers Yes","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001017,"latencyMs":4506,"response":"Yes. In India, the fixed-dose combination of paracetamol and lignocaine is prohibited for manufacture, sale and distribution under Section 26A of the Drugs and Cosmetics Act (S.O. 3079(E), 11 June 2026). [1]"}
{"id":"in-prohibited-SO3308E","category":"india-prohibited","passed":true,"checks":[{"description":"Answers Yes","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001144,"latencyMs":5828,"response":"Yes. In India, the fixed-dose combination povidone iodine + metronidazole + aloe is prohibited for manufacture, sale and distribution under Section 26A of the Drugs and Cosmetics Act, as listed in CDSCO notification S.O. 3308(E) dated 2 August 2024. [3]"}
{"id":"in-prohibited-SO3402E","category":"india-prohibited","passed":true,"checks":[{"description":"Answers Yes","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001029,"latencyMs":4449,"response":"Yes. This fixed-dose combination is prohibited in India for manufacture, sale and distribution under Section 26A of the Drugs and Cosmetics Act, as specified in S.O. 3402(E), dated 2 August 2024. [1]"}
{"id":"in-prohibited-SO3300E","category":"india-prohibited","passed":true,"checks":[{"description":"Answers Yes","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001088,"latencyMs":5320,"response":"Yes. Sucralfate + aceclofenac is prohibited in India for manufacture, sale and distribution under Section 26A of the Drugs and Cosmetics Act (S.O. 3300(E), dated 2 August 2024). [3]"}
{"id":"in-prohibited-SO3337E","category":"india-prohibited","passed":true,"checks":[{"description":"Answers Yes","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001167,"latencyMs":4468,"response":"Yes. In India, “Tetracycline + Colistin Sulphate” is prohibited under Section 26A of the Drugs and Cosmetics Act by S.O. 3337(E), dated 2 August 2024. [3]"}
{"id":"in-permitted-nlem-6.7.1.2","category":"india-prohibited-control","passed":true,"checks":[{"description":"Answers No","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001389,"latencyMs":5174,"response":"No. The evidence provided does not show that abacavir + lamivudine is prohibited for manufacture, sale, or distribution in India. Both abacavir and lamivudine are listed in India’s National List of Essential Medicines 2022; that listing does not, by itself, confirm the legal status of a fixed-dose combination. [3]"}
{"id":"in-permitted-nlem-6.10.1.1","category":"india-prohibited-control","passed":true,"checks":[{"description":"Answers No","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001459,"latencyMs":7264,"response":"No. The evidence provided does not list artemether + lumefantrine as prohibited in India; it says only that neither ingredient is on India’s National List of Essential Medicines 2022 [2]. I could not verify the current CDSCO prohibition status from the available sources."}
{"id":"in-permitted-nlem-6.7.4.1","category":"india-prohibited-control","passed":true,"checks":[{"description":"Answers No","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001328,"latencyMs":5081,"response":"No. The retrieved evidence does not establish that the fixed-dose combination is prohibited in India. The available CDSCO information supplied here contains no entry addressing this combination. Atazanavir is not listed in India’s NLEM 2022, while ritonavir is listed; neither fact determines whether the combination is prohibited. [3]"}
{"id":"in-permitted-nlem-6.2.2.6","category":"india-prohibited-control","passed":true,"checks":[{"description":"Answers No","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001039,"latencyMs":4391,"response":"No. The supplied evidence does not establish that co-trimoxazole is prohibited for manufacture, sale or distribution in India. It says only that sulfamethoxazole and trimethoprim are not listed in India’s NLEM 2022; absence from that list does not mean the combination is prohibited."}
{"id":"in-permitted-nlem-11.4.2","category":"india-prohibited-control","passed":true,"checks":[{"description":"Answers No","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.000908,"latencyMs":4283,"response":"No. The evidence provided does not show the fixed-dose combination coal tar + salicylic acid as prohibited for manufacture, sale or distribution in India. It only notes that coal tar is not on India’s NLEM 2022, while salicylic acid is listed; NLEM status does not establish whether a combination is prohibited. I cannot confirm the combination’s current prohibition status from the evidence available."}
{"id":"in-permitted-nlem-18.2.1.1","category":"india-prohibited-control","passed":true,"checks":[{"description":"Answers No","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001252,"latencyMs":7561,"response":"No. The retrieved evidence does not establish that the fixed-dose combination ethinylestradiol + levonorgestrel is prohibited in India. It only states that ethinylestradiol is not on India’s National List of Essential Medicines 2022 and that levonorgestrel is listed; NLEM status is not a prohibition [2]."}
{"id":"in-permitted-nlem-25.1.2","category":"india-prohibited-control","passed":true,"checks":[{"description":"Answers No","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.000885,"latencyMs":7599,"response":"No. I could not verify that the fixed-dose combination **glucose + sodium chloride** is prohibited for manufacture, sale and distribution in India from the sources retrieved. PubMed did not return relevant records, and it is not an authoritative source for Indian drug-ban notifications. Check the current Ministry of Health and Family Welfare/Central Drugs Standard Control Organisation notifications for a definitive legal determination."}
{"id":"in-permitted-nlem-1.2.3","category":"india-prohibited-control","passed":true,"checks":[{"description":"Answers No","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001116,"latencyMs":9952,"response":"No. I cannot verify the current CDSCO prohibition list from the evidence available in this turn, so treat this as **unconfirmed** and check the latest CDSCO notification before relying on it for a regulatory decision."}
{"id":"in-permitted-nlem-6.7.1.5","category":"india-prohibited-control","passed":true,"checks":[{"description":"Answers No","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001333,"latencyMs":6181,"response":"No. The supplied evidence lists tenofovir disoproxil fumarate and lamivudine individually in India’s NLEM 2022, but it does not establish whether their fixed-dose combination is prohibited for manufacture, sale or distribution. [3]"}
{"id":"in-permitted-nlem-6.7.1.7","category":"india-prohibited-control","passed":true,"checks":[{"description":"Answers No","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001203,"latencyMs":4017,"response":"No. The supplied CDSCO information does not identify this fixed-dose combination as prohibited for manufacture, sale or distribution in India. The supplied NLEM excerpt lists the individual medicines, but that does not by itself establish the combination’s approval or availability."}
{"id":"nlem-listed-6.7.1.1","category":"nlem","passed":true,"checks":[{"description":"Answers Yes","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001151,"latencyMs":4353,"response":"Yes. Abacavir is listed on India’s National List of Essential Medicines 2022 at secondary and tertiary levels of care, in 60 mg and 300 mg tablet forms. [2]"}
{"id":"nlem-listed-1.3.1","category":"nlem","passed":true,"checks":[{"description":"Answers Yes","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001046,"latencyMs":4928,"response":"Yes. Atropine is on India’s National List of Essential Medicines 2022, listed for use at primary, secondary and tertiary levels of care in injection, drops and ointment formulations. [2]"}
{"id":"nlem-listed-21.6.1","category":"nlem","passed":true,"checks":[{"description":"Answers Yes","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001,"latencyMs":5029,"response":"Yes. Carboxymethyl cellulose is listed in India’s National List of Essential Medicines 2022 as an ophthalmological medicine, with 0.5% and 1% drops listed at primary, secondary and tertiary levels of care. [2]"}
{"id":"nlem-listed-23.1.1","category":"nlem","passed":true,"checks":[{"description":"Answers Yes","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.00118,"latencyMs":7568,"response":"Yes. Clozapine is on India’s National List of Essential Medicines 2022 for psychiatric disorders at the tertiary level of care; listed strengths are 25 mg, 50 mg and 100 mg tablets. [4]"}
{"id":"nlem-listed-17.2.1","category":"nlem","passed":true,"checks":[{"description":"Answers Yes","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.000982,"latencyMs":4324,"response":"Yes. Domperidone is listed in India’s National List of Essential Medicines 2022 under gastrointestinal medicines, at primary, secondary and tertiary levels of care. Listed forms are 10 mg tablets and 1 mg/mL oral liquid. [1]"}
{"id":"nlem-listed-11.2.2","category":"nlem","passed":true,"checks":[{"description":"Answers Yes","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.00098,"latencyMs":4299,"response":"Yes. Fusidic acid is listed in India’s National List of Essential Medicines 2022 as a topical dermatological medicine (2% cream), at primary, secondary and tertiary levels of care. [1]"}
{"id":"nlem-listed-2.1.3","category":"nlem","passed":true,"checks":[{"description":"Answers Yes","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001127,"latencyMs":5053,"response":"Yes. Ibuprofen is listed in India’s National List of Essential Medicines 2022 at primary, secondary and tertiary levels of care. Listed forms are 200 mg and 400 mg tablets, and oral liquid 100 mg/5 mL [3]."}
{"id":"nlem-listed-6.4.11","category":"nlem","passed":true,"checks":[{"description":"Answers Yes","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001154,"latencyMs":6010,"response":"Yes. Linezolid is included in India’s National List of Essential Medicines 2022, at primary, secondary, and tertiary levels of care; listed forms are 300 mg and 600 mg tablets. [2]"}
{"id":"nlem-listed-2.2.2","category":"nlem","passed":true,"checks":[{"description":"Answers Yes","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001174,"latencyMs":5415,"response":"Yes. Morphine is on India’s National List of Essential Medicines 2022, listed at primary, secondary and tertiary levels of care. Listed forms include injection (10 mg/mL and 15 mg/mL), tablet (10 mg), and modified-release tablet (30 mg). [4]"}
{"id":"nlem-listed-13.2","category":"nlem","passed":true,"checks":[{"description":"Answers Yes","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001165,"latencyMs":6028,"response":"Yes. Peritoneal dialysis solution is listed in India’s National List of Essential Medicines 2022 under dialysis components (haemodialysis and peritoneal dialysis), at secondary and tertiary levels of care; the listed forms are “as licensed.” [1]\n\n### When to escalate\nSeek urgent review if dialysis fluid becomes cloudy, or if abdominal pain or fever develops; these may indicate peritonitis. Urgent assessment is also needed for difficulty draining fluid, new breathlessness or swelling, or feeling faint or severely unwell. Reassess promptly if any of these occur; otherwise, continue follow-up with the dialysis team."}
{"id":"nlem-listed-26.6","category":"nlem","passed":true,"checks":[{"description":"Answers Yes","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001099,"latencyMs":5255,"response":"Yes. Riboflavin is listed in India’s National List of Essential Medicines 2022 as a 10 mg tablet, at primary, secondary, and tertiary levels of care. [2]"}
{"id":"nlem-listed-10.5.7","category":"nlem","passed":true,"checks":[{"description":"Answers Yes","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001121,"latencyMs":4405,"response":"Yes. Tenecteplase is listed in India’s National List of Essential Medicines 2022 under cardiovascular medicines, at secondary and tertiary levels of care; the listed forms are 30 mg/vial and 40 mg/vial. [2]"}
{"id":"nlem-not-listed-nimesulide","category":"nlem","passed":true,"checks":[{"description":"Answers No","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.000964,"latencyMs":4315,"response":"No. Nimesulide is not listed in India’s National List of Essential Medicines 2022. [2]"}
{"id":"nlem-not-listed-aceclofenac","category":"nlem","passed":true,"checks":[{"description":"Answers No","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.000964,"latencyMs":5400,"response":"No. Aceclofenac is not listed in India’s National List of Essential Medicines 2022 [2]."}
{"id":"nlem-not-listed-etoricoxib","category":"nlem","passed":true,"checks":[{"description":"Answers No","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.000866,"latencyMs":13830,"response":"<scratchpad>Checked whether etoricoxib appears in India’s National List of Essential Medicines 2022. The PubMed search returned no supporting records; no authoritative list document was retrieved.</scratchpad>\n\nNo. I could not retrieve the official NLEM 2022 document in this check, so this answer is not independently source-verified here.\n\n### When to escalate\nNo patient-specific findings or clinical changes are provided, so urgent review, referral, admission, or a reassessment interval cannot be specified."}
{"id":"nlem-not-listed-trimetazidine","category":"nlem","passed":true,"checks":[{"description":"Answers No","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.000958,"latencyMs":4062,"response":"No. Trimetazidine is not on India’s National List of Essential Medicines 2022. [1]"}
{"id":"nlem-not-listed-flucloxacillin","category":"nlem","passed":true,"checks":[{"description":"Answers No","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.000969,"latencyMs":5392,"response":"No. Flucloxacillin is not listed in India’s National List of Essential Medicines 2022. [1]"}
{"id":"nlem-not-listed-cefoperazone","category":"nlem","passed":true,"checks":[{"description":"Answers No","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.000964,"latencyMs":4149,"response":"No. Cefoperazone is not on India’s National List of Essential Medicines 2022 [1]."}
{"id":"nlem-not-listed-ornidazole","category":"nlem","passed":true,"checks":[{"description":"Answers No","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.000964,"latencyMs":5324,"response":"No. Ornidazole is not on India’s National List of Essential Medicines 2022 [1]."}
{"id":"nlem-not-listed-drotaverine","category":"nlem","passed":true,"checks":[{"description":"Answers No","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.000958,"latencyMs":4392,"response":"No. Drotaverine is not listed in India’s National List of Essential Medicines 2022. [1]"}
{"id":"fda-ferric-carboxymaltose-2026-true","category":"fda-safety-recent","passed":true,"checks":[{"description":"Answers Yes","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001191,"latencyMs":4239,"response":"Yes. On September 1, 2026, the FDA announced a boxed warning for ferric carboxymaltose injection (Injectafer) describing the risk of low phosphate levels. [3]"}
{"id":"fda-ferric-carboxymaltose-2026-false","category":"fda-safety-recent","passed":true,"checks":[{"description":"Answers No","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.00136,"latencyMs":5089,"response":"No. The retrieved FDA labeling effective August 19, 2026, includes a boxed warning for symptomatic hypophosphatemia, and an FDA Drug Safety Communication dated September 1, 2026, says the boxed warning was added—not removed. [2][3]"}
{"id":"fda-glp1-suicidality-2026-true","category":"fda-safety-recent","passed":true,"checks":[{"description":"Answers Yes","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001432,"latencyMs":6188,"response":"Yes. On 13 January 2026, the FDA requested removal of the suicidal behavior and ideation warning from GLP-1 receptor agonist medications. [4]"}
{"id":"fda-glp1-suicidality-2026-false","category":"fda-safety-recent","passed":true,"checks":[{"description":"Answers No","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001421,"latencyMs":4368,"response":"No. On January 13, 2026, the FDA requested removal of the suicidal behavior and ideation warning from GLP-1 receptor agonist medications, rather than adding one. [4]"}
{"id":"fda-clozapine-rems-2025-true","category":"fda-safety-recent","passed":true,"checks":[{"description":"Answers Yes","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.000511,"latencyMs":4571,"response":"Yes. The FDA removed the clozapine REMS program on August 27, 2025. [2]"}
{"id":"fda-clozapine-rems-2025-false","category":"fda-safety-recent","passed":true,"checks":[{"description":"Answers No","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.000548,"latencyMs":4385,"response":"No. In August 2025, the FDA removed the clozapine REMS program; it did not introduce a stricter one. Clozapine’s serious safety risks and the need for appropriate monitoring remain [2]."}
{"id":"fda-carbidopa-levodopa-b6-2026-true","category":"fda-safety-recent","passed":true,"checks":[{"description":"Answers Yes","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001319,"latencyMs":6187,"response":"Yes. On March 20, 2026, the FDA announced it was requiring a warning about vitamin B6 deficiency and associated seizures for products containing carbidopa/levodopa. [4]"}
{"id":"fda-carbidopa-levodopa-b6-2026-false","category":"fda-safety-recent","passed":true,"checks":[{"description":"Answers No","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.000543,"latencyMs":4506,"response":"No. On March 20, 2026, the FDA announced it was requiring a warning about vitamin B6 deficiency and associated seizures for carbidopa/levodopa products. [4]"}
{"id":"fda-orlistat-kidney-2026-true","category":"fda-safety-recent","passed":true,"checks":[{"description":"Answers Yes","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001138,"latencyMs":4731,"response":"Yes. On June 10, 2026, the FDA announced labeling changes for over-the-counter orlistat (alli) warning about kidney stones and kidney injury. [2]"}
{"id":"fda-orlistat-kidney-2026-false","category":"fda-safety-recent","passed":true,"checks":[{"description":"Answers No","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001198,"latencyMs":5192,"response":"No. The FDA communication cited here says it approved labeling changes for OTC orlistat to warn about kidney stones and kidney injury; it does not say the product was withdrawn from the market [3]."}
{"id":"fda-cetirizine-itching-2025-true","category":"fda-safety-recent","passed":true,"checks":[{"description":"Answers Yes","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001265,"latencyMs":4611,"response":"Yes. On May 16, 2025, the FDA required a warning about rare but severe itching that can occur after stopping long-term use of oral cetirizine or levocetirizine. [4]"}
{"id":"fda-cetirizine-itching-2025-false","category":"fda-safety-recent","passed":true,"checks":[{"description":"Answers No","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001213,"latencyMs":4584,"response":"No. In 2025, the FDA required a warning about rare but severe itching after stopping long-term use of oral cetirizine or levocetirizine; it did not restrict them to prescription-only use. [3]"}
